There have been many advancements in chemotherapy and immunotherapy treatments for various cancers over the past decade, but the 5-year relative survival rate for glioblastoma patients is still around 10%. Since glioblastoma is a rare condition, an RO-1 grant from the FDA has been awarded to GenSpera, Inc. for its research on G-202′s (mipsagargin’s) efficacy in treating recurrent glioblastoma.
G-202 is a prodrug, a toxic substance made dormant by attaching a peptide that allows the toxin to be released in only those cells that express the desired characteristics. In this case, the prodrug targets cells with a high level of PSMA expression, a protein that is present in many cancerous tumors. According to Dr. Kesari, Phase II study results look promising and no serious adverse events have been observed to date.
Santosh Kesari, MD, PhD
Scientific Advisory Board Member: GenSpera, Inc.